tolbutamide (orinase) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.   NCATS

Chemistry

More Chemistry

Pharmacology

Alternative names

1-butyl-3-(p-methylphenylsulfonyl)urea | 1-butyl-3-(p-tolylsulfonyl)urea | 1-butyl-3-tosylurea | 1-p-toluenesulfonyl-3-butylurea | 3-(p-tolyl-4-sulfonyl)-1-butylurea | aglicid | arkozal | glyconon | n-(4-methylbenzenesulfonyl)-n'-butylurea | n-(4-methylphenylsulfonyl)-n'-butylurea | n-butyl-n'-(4-methylphenylsulfonyl)urea | n-butyl-n'-p-toluenesulfonylurea | n-butyl-n'-(p-tolylsulfonyl)urea | n-n-butyl-n'-tosylurea | n-(p-methylbenzenesulfonyl)-n'-butylurea | n-(sulfonyl-p-methylbenzene)-n'-n-butylurea | orinase | orinase diagnostic | orinase (tn) | pramidex | rastinon | tolbutamid | tolbutamida | tolbutamide | tolbutamide sodium | tolbutamide sodium, sterile | tolbutamidum | tolumid | tolumide | tolylsulfonylbutylurea

Organizations (36)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Chronic Pain (Phase 1)

Drug Interactions (Phase 1)

Endotoxemia (Phase 1)

Food-Drug Interactions (Phase 1)

Healthy Volunteers (Phase 1)

Hepatitis C, Chronic (Phase 1)

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 17
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue